Date: Thu, 18 Dec 1997 17:52:05 GMT
Server: Apache/1.2.4
Last-Modified: Thu, 30 Oct 1997 19:29:45 GMT
ETag: "9a5a-1714-3458e029"
Content-Length: 5908
Accept-Ranges: bytes
Connection: close
Content-Type: text/html

<!DOCTYPE HTML PUBLIC "-//IETF//DTD HTML//EN">

<html>

<head>

<meta name="GENERATOR" content="Microsoft FrontPage 2.0">
<title>Scientific Advisory Board</title>

</head>

<body stylesrc="index.htm" background="images/Background.jpg" bgcolor="#FFFFFF">

<p align="center"><font color="#FF0000" size="6"><strong>Avigen
Scientific Advisory Board</strong></font></p>

<p align="left"><font color="#000000" size="3" face="MS Sans Serif"><strong>Gary J. Kurtzman, M.D.,</strong></font><font color="#008040" size="2" face="MS Sans Serif"><strong> </strong></font><font size="2" face="MS Sans Serif">is Chairman of the Scientific
Advisory Board. Dr. Kurtzman serves as Vice President, Research
and Development for the Company. &quot;See </font><a href="board.htm#Gary J. Kurtzman"><font size="2" face="MS Sans Serif">Management, Directors and Executive Officers</font></a><font size="2" face="MS Sans Serif">.&quot;<br>
<br>
</font><font color="#000000" size="3" face="MS Sans Serif"><strong>Jef
D. Boeke, Ph.D., </strong></font><font size="2" face="MS Sans Serif">co-invented capsid targeted viral
inactivation technology that provides a basis for Avigen's
infectious disease product development program. Dr. Boeke is a
professor of Molecular Biology and Genetics at The Johns Hopkins
University School of Medicine and has authored more than 100
publications.<br>
<br>
</font><font color="#000000" size="3" face="MS Sans Serif"><strong>Jerome
E. Groopman, M.D.</strong></font><font size="2" face="MS Sans Serif"> serves as chief of Hematology/Oncology at
Harvard University's New England Deaconess Hospital in Boston and
holds the Dina and Raphael Recantati Chair at Harvard Medical
School. In addition, Dr. Groopman serves on the Board of
Directors of the American Foundation for AIDS Research and is a
member of the FDA Biological Response Modifiers Advisory
Committee.</font></p>

<p align="left"><font color="#000000" size="3" face="MS Sans Serif"><strong>Mark A. Israel, M.D., </strong></font><font size="2" face="MS Sans Serif">is Professor of Neurological
Surgery and Pediatrics and Director, The Preuss Laboratory of
Molecular Neuro-oncology at the University of California, San
Francisco. Prior to that, Dr. Israel was Head, Molecular Genetics
Section in the Pediatric Branch of the National Cancer Institute.
Dr. Israel&#146;s research has focused on the molecular and
cellular biology of tumors of the nervous system and has authored
more than 150 publications. In addition, he has received numerous
honors for his work in this field and is a member of the
editorial boards of a number of scientific journals. <br>
<br>
</font><font color="#000000" size="3" face="MS Sans Serif"><strong>Yuichi
Iwaki, M.D., Ph.D. </strong></font><font size="2" face="MS Sans Serif">serves as a director of the Company.
&quot;See Management &#151; Directors and Executive
Officers.&quot;<br>
<br>
</font><font color="#000000" size="3" face="MS Sans Serif"><strong>Y.W.
Kan, M.D., D.Sc.</strong></font><font size="2" face="MS Sans Serif"> is the Louis K. Diamond Professor of
Hematology at the University of California at San Francisco. He
also is an Investigator of the Howard Hughes Medical Institute.
Dr. Kan was the 1991 recipient of the Albert Lasker Clinical
Medical Research Award and is noted as a leader in the fields of
sickle cell anemia and thalassemia.<br>
<br>
</font><font color="#000000" size="3" face="MS Sans Serif"><strong>Keiya
Ozawa, M.D., Ph.D. </strong></font><font size="2" face="MS Sans Serif">is a professor of Molecular Biology,
Institute of Hematology, at Jichi Medical School in Japan, where
he has established a research and preclinical program in gene
therapy. Dr. Ozawa is regarded as one of the leading authorities
on gene therapy in Japan and is responsible for drafting the
Japanese government's gene therapy guidelines. Dr. Ozawa holds
both a M.D. and a Ph.D. from the University of Tokyo and is the
author of more than 90 publications regarding virology,
hematology and gene therapy.<br>
<br>
</font><font color="#000000" size="3" face="MS Sans Serif"><strong>Jeffrey
M. Rosen, Ph.D. </strong></font><font size="2" face="MS Sans Serif">is a professor of Cell Biology at Baylor
College of Medicine. Dr. Rosen is an internationally recognized
expert in the field of gene expression. His research has focused
primarily on the mechanisms of tissue-specific gene expression in
the mammary and prostate glands. Dr. Rosen has served on the
editorial board of the Journal of Biological Chemistry, Molecular
and Cellular Endocrinology, Molecular Endocrinology and as
executive editor of Nucleic Acids Research.</font></p>

<hr>
<!--webbot bot="Include" tag="BODY" u-include="_private/navbar.htm" startspan -->

<p><a href="index.htm"><img src="images/HomePage.gif" alt="HomePage" style="border: 0" border="0" width="119" height="36"></a><a href="news.htm" target><img src="images/WhatsNew.gif" alt="WhatsNew" style="border: 0" border="0" width="119" height="36"></a><a href="AAV_Info.htm" target><img src="images/AAV%20Vectors.gif" alt="AAV Vectors" style="border: 0" border="0" width="119" height="36"></a><a href="http://www.nasdaq.com/scripts/quote.dll?symbol=avgn&amp;mode=stock+quote" target><img src="images/Nasdaq.gif" alt="Nasdaq-AVGN" style="border: 0" border="0" width="119" height="36"></a><a href="jobs.htm" target><img src="images/Employment.gif" alt="Employment" style="border: 0" border="0" width="119" height="36"></a><a href="CorporatePartners.htm" target><img src="images/CorpPartners.gif" alt="Corporate Partners" style="border: 0" border="0" width="119" height="36"></a><a href="toc.htm" target><img src="images/Contents.gif" alt="Table of Contents" style="border: 0" border="0" width="119" height="36"></a></p>
<!--webbot bot="Include" endspan i-checksum="34220" -->
</body>
</html>
